Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00517543 · ClinicalTrials.gov registry record · Phase 1
A Study to Examine the Effect of Particle Size on Bioequivalence and Bioavailability
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00517543 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 36 participants.
The verdict
NCT00517543, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This study is being conducted to measure the amount of study drug that is in your blood after you receive a different type of tablet in each of four study visits.
Interventions
- DRUG GW856553
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2007-08 |
| Est. Completion | 2007-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00517543
The ClinicalTrials.gov registry entry for NCT00517543 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GW856553 is the first listed.
NCT00517543 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00517543 about?
NCT00517543 is a clinical study titled "A Study to Examine the Effect of Particle Size on Bioequivalence and Bioavailability". This study is being conducted to measure the amount of study drug that is in your blood after you receive a different type of tablet in each of four study visits.
What is the current status of trial NCT00517543?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2007-08. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00517543?
The interventions under investigation include: GW856553 (DRUG).
Who is sponsoring clinical trial NCT00517543?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.